The combined effects of NR4A1 antagonists in both tumors and T-cells (Fig. 7D) result in potent inhibition of colon tumorigenesis by targeting pathways/genes including PD-L1 in tumor cells and by enhancing immune surveillance through inhibition of NR4A1-dependent T-cell dysfunction in TILs and splenic infiltrating lymphocytes. Here, CD274 is linked to neoplasm.